ESGV vs IBB
Vanguard ESG US Stock ETF vs iShares Biotechnology ETF
- • ESGV has the lower expense ratio at 0.09% vs 0.44% for IBB.
- • ESGV pays a higher dividend yield (0.90%).
Side-by-side metrics
| Metric | ESGV | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.09% | 0.44% |
Dividend yield Trailing 12-month yield. | 0.90% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $13.04B | $11.50B |
YTD return | 10.67% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.11 | 0.60 |
P/E ratio | 24.03 | 25.48 |
Last price | $134.43 | $217.75 |
Inception | — | — |
Issuer | Vanguard | iShares |
ESGV top holdings
| NVDA | NVIDIA Corp | 8.92% |
| AAPL | Apple Inc | 8.06% |
| MSFT | Microsoft Corp | 6.38% |
| AMZN | Amazon.com Inc | 4.05% |
| GOOGL | Alphabet Inc Class A | 3.35% |
| AVGO | Broadcom Inc | 2.73% |
| GOOG | Alphabet Inc Class C | 2.71% |
| META | Meta Platforms Inc Class A | 2.67% |
| MU | Micron Technology Inc | 2.01% |
| TSLA | Tesla Inc | 1.73% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About ESGV
ESGV (Vanguard ESG US Stock ETF) is Broad US market with ESG screens applied. Managed by Vanguard, the fund carries $13.0B in assets under management, an expense ratio of 0.09%, a dividend yield of 0.90%. Its largest holding is NVIDIA Corp (NVDA), which represents 8.9% of the portfolio. Real Estate is the fund's largest sector exposure at 2.5%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.